<DOC>
	<DOCNO>NCT02484716</DOCNO>
	<brief_summary>Timolol nonselective β-blocker commonly use treatment glaucoma . Recently use topically treatment superficial hemangioma . Because potential mechanism action , possible timolol could also useful treatment epistaxis Hereditary Hemorrhagic Telangiectasia ( HHT ) . Moreover case report 2012 show improvement nosebleed use topical nasal timolol . The aim study evaluate timolol nasal spray efficacy HHT . The main objective trial evaluate , 3 month end treatment , efficacy duration nosebleeds 4 week timolol intranasal treatment HHT patient nosebleed ( &gt; 20 min/month ) . Secondary objective evaluate tolerance , efficacy 6 month end treatment , efficacy anemia clinical parameter ( nosebleed , quality life blood transfusion ) . This prospective double blind phase II study , randomize versus placebo use allocation ratio 1:1 . A total 58 patient include . The product ( solution timolol 0.5 % placebo ) self-administered patient posology one spray ( 50 µL ) nostril twice day 28 consecutive day .</brief_summary>
	<brief_title>Efficacy Timolol Nasal Spray Treatment Epistaxis Hereditary Hemorrhagic Telangiectasia ( HHT ) - ( TEMPO )</brief_title>
	<detailed_description />
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Epistaxis</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Age &gt; 18 year Patients give voluntary , informed consent sign consent form . Patients affiliate French universal health care system Patients treat HHT , confirm clinically ( presence least 3 Curaçao criterion ) and/or molecular biology . Patients present epistaxis average 20 minute three month inclusion , justify complete epistaxis tally sheet . Pregnant woman woman could become pregnant study , lactation Patients affiliate French universal health care system Patients protect adult accord term law ( French public health law ) . Refusal give consent . Patients whose HHT diagnosis confirm clinically and/or molecular biology . Participation another therapeutic trial could interfere present trial ( investigator jugement ) . Bronchial asthma , presence history severe chronic obstructive pulmonary disease Cardiac history : cardiac failure cardiogenic shock . Atrioventricular block ( second third degree ) control pacemaker sinus disease ( included sinoatrial block ) confirm ECG less one year . Ongoing treatment calcium antagonist ( bépridil , diltiazem , verapamil ) antiarrhytmics ( propafénone , quinidine , hydroquinidine , disopyramide ) clonidine lidocaîne . Ongoing betablocker treatment . Bradycardia ( &lt; 50 pulse per minute ) Hypotension ( PAS &lt; 90 Hg mm ) Angina Not control Pheochromocytoma Severe peripheral circulatory disturbance ( Raynaud disease ) Hypersensitivity active substance , excipients betablocking agent Ongoing treatment floctafénine sultopride amiodarone Patients complete epistaxis grid three month treatment Patients present epistaxis average 20 minute three month inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hemorrhagic Hereditary Telangiectasia ( HHT )</keyword>
	<keyword>Antiangiogenic therapy</keyword>
	<keyword>Timolol</keyword>
</DOC>